What is the effect size of aripiprazole (Abilify) when used as augmentation for difficult-to-treat major depressive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Effect Size of Aripiprazole for Difficult-to-Treat Depression

Aripiprazole augmentation demonstrates a clinically meaningful effect size in treatment-resistant major depressive disorder, with a number needed to treat (NNT) of 6-7 for response and 8 for remission, representing moderate efficacy when added to ongoing antidepressant therapy.

Quantified Clinical Benefits

The most robust evidence comes from pooled analyses of three large randomized controlled trials showing:

  • Response rates: 36% with aripiprazole augmentation vs 19% with placebo (NNT = 6) 1
  • Remission rates: 24% vs 12% (NNT = 8) 1
  • Mean symptom reduction: Additional 3-4 point improvement on the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo 2

These effect sizes translate to meaningful clinical improvement, with benefits emerging as early as week 1-2 and maintained through 6 weeks of treatment 3.

Response Patterns by Severity

Aripiprazole augmentation shows differential response rates based on initial treatment response 4:

  • Partial response (>25-50% improvement): 23.9% vs 17.9% placebo
  • Moderate response (≥50-75% improvement): 23.1% vs 15.0% placebo
  • Robust response (≥75% improvement): 14.3% vs 7.4% placebo

Critically, patients showing minimal initial response (<25% improvement to first antidepressant) still benefited significantly from aripiprazole augmentation, with response rates of 36% vs 19% placebo 1. This is particularly relevant for truly difficult-to-treat cases.

Optimal Dosing for Effect Size

The dose-response curve plateaus between 2-5 mg/day, with no additional efficacy benefit at higher doses up to 20 mg/day 5. The FDA-approved range is 2-15 mg/day for augmentation 6, but:

  • 2 mg/day: OR 1.46 (95% CI 1.15-1.85) for response
  • 5 mg/day: OR 1.93 (95% CI 1.33-2.81) for response
  • 20 mg/day: OR 1.90 (95% CI 1.52-2.37) for response

Start at 2-5 mg/day and increase only if inadequate response after 2 weeks, as higher doses increase side effects without improving efficacy 57.

Predictive Value of Early Response

An early response at week 2 (≥50% MADRS reduction) is a significant predictor of sustained remission 4. This allows clinicians to make informed decisions about continuing or adjusting treatment within 2 weeks rather than waiting the traditional 4-6 weeks.

Comparative Context

The 2023 ACP guideline systematic review found that different augmentation strategies (aripiprazole, bupropion, buspirone) provide similar symptomatic relief with low certainty of evidence for most comparisons 888. However, aripiprazole has the most robust trial data specifically for augmentation in treatment-resistant depression 2.

Safety Trade-offs Affecting Real-World Effect Size

While efficacy is moderate, tolerability concerns limit real-world effectiveness 8:

  • Akathisia: Most common limiting side effect
  • Weight gain: Dose-dependent, more prominent at higher doses
  • Sedation: Can be beneficial or problematic depending on patient
  • Discontinuation due to adverse events: Higher than placebo but comparable to other augmentation strategies

Real-world Japanese data showed 24.8% experienced adverse events, but effectiveness was maintained with 43.3% achieving remission by 12 months 9.

Clinical Algorithm for Maximizing Effect Size

  1. Confirm inadequate response to at least one adequate antidepressant trial (adequate dose × 6-8 weeks)
  2. Start aripiprazole 2-5 mg/day as augmentation to ongoing antidepressant 65
  3. Assess at week 2: If ≥50% improvement, continue; if <50% improvement, consider increasing to 6-12 mg/day 7
  4. Reassess at week 6: If inadequate response, consider switching strategies rather than exceeding 12 mg/day 5
  5. Factors favoring better response: Baseline MADRS <33, shorter duration of current episode (<176 days) 9

Critical Caveats

  • Certainty of evidence is low to moderate for most comparisons in the guideline literature 88
  • Effect sizes are based on highly selected trial populations with moderate-to-severe depression; applicability to mild depression is uncertain 8
  • The absence of placebo groups in some comparisons makes it difficult to distinguish true equivalence from high placebo response rates 8
  • Long-term efficacy and safety data beyond 6 weeks are limited in controlled trials, though real-world data suggest sustained benefit up to 12 months 9

References

2
Research

Second-generation antipsychotics for major depressive disorder and dysthymia.

The Cochrane database of systematic reviews, 2010

Related Questions

Can aripiprazole be added as augmentation therapy for an adult patient with major depressive disorder who has not achieved adequate improvement after an adequate (≥6 weeks) trial of a therapeutic dose of an SSRI or SNRI?
Should aripiprazole be used instead of fluoxetine as first‑line therapy for depression?
Should the aripiprazole dose be increased from 15 mg daily for a patient with ongoing hypomania, disorganization, and anxiety while on lamotrigine 200 mg daily?
How should aripiprazole be increased from 5 mg to 10 mg in a patient who previously tolerated brexpiprazole?
For a patient with long‑standing atypical depression, partial response to an SSRI, and concern for bipolar spectrum, is it appropriate to initiate aripiprazole (5 mg) as an augmenting agent?
What is the likely diagnosis for bilateral medial elbow pain affecting the ulnar nerves?
I have hyperadrenergic postural orthostatic tachycardia syndrome (POTS) with controlled heart rate, but I still experience post‑prandial discomfort, tension, and feeling on edge after meals; how can I alleviate these symptoms?
What are the causes of a low reticulocyte production index (RPI) in a septic patient with bicytopenia?
How often should laboratory monitoring be performed for patients on isotretinoin?
What is the recommended fluconazole dosing regimen for candidemia, including loading and maintenance doses and adjustments for renal impairment?
In a 21‑week pregnant woman with a history of miscarriage, which chronic diseases should be screened for?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.